All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Antiviral therapy for the hepatitis C virus (HCV) reduces all-cause and liver-related morbidity and mortality. Few studies are available from populations with multiple medical and psychiatric comorbidities where the impact of successful antiviral therapy might be limited.
The purpose of this study was to determine the effect of sustained virologic response (SVR) on all-cause and liver-related mortality in a cohort of HCV patients treated in an integrated hepatitis/mental health clinic.
This was a retrospective review of all patients who initiated antiviral treatment for chronic HCV between January 1, 1997 and December 31, 2009. Cox regression analysis was used to determine factors involved in all-cause mortality, liver-related events and hepatocellular carcinoma.
A total of 536 patients were included in the analysis. Median follow-up was 7.5 years. Liver and non-liver-related mortality occurred in 2.7 and 5.0 % of patients with SVR and in 17.8 and 6.4 % of patients without SVR. In a multivariate analysis, SVR was the only factor associated with reduced all-cause mortality (HR 0.47; 95 % CI 0.26–0.85; p = 0.012) and reduced liver-related events (HR 0.23; 95 % CI 0.08–0.66, p = 0.007). Having stage 4 liver fibrosis increased all-cause mortality (HR 2.50; 95 % CI 1.23–5.08; p = 0.011). Thrombocytopenia at baseline (HR 2.66; 95 % CI 1.22–5.79; p = 0.014) and stage 4 liver fibrosis (HR 4.87; 95 % CI 1.62–14.53; p = 0.005) increased liver-related events.
Despite significant medical and psychiatric comorbidities, SVR markedly reduced liver-related outcomes without a significant change in non-liver-related mortality after a median follow-up of 7.5 years.
- Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti-Infect Ther. 2005;3:241–249. CrossRef
- Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513–521. CrossRef
- Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–398, vi.
- Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–278. CrossRef
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416. CrossRef
- Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206. CrossRef
- Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
- Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
- Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–288.
- Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587. CrossRef
- Fernandez-Rodriguez CM, Alonso S, Martinez SM et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105:2164–2172; quiz 2173.
- Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844. CrossRef
- van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593. CrossRef
- Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684. CrossRef
- Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129:1254–1264. CrossRef
- Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–516.
- Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. Management of chronic hepatitis C in veterans: the potential of integrated care models. Am J Gastroenterol. 2008;103:1810–1823. CrossRef
- Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262. CrossRef
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis. The METAVIR cooperative study group. Hepatology. 1996;24:289–293. CrossRef
- Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther. 2013;37:887–894. CrossRef
- Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8:1017–1029. CrossRef
- Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279–1287. CrossRef
- Bleibel W, Caldwell SH, Curry MP, Northup PG. Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list. Transpl Int. 2013;26:435–442. CrossRef
- Evon DM, Simpson K, Kixmiller S, et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106:1777–1786. CrossRef
- Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52:430–435. CrossRef
- Ho SB, Groessl EJ, Brau N, et al. Multisite randomized trial of an Integrated Care (IC) model for HCV patients with psychiatric and substance use co-morbidities: final results of impact on treatment initiation. Hepatology. 2012;56:1000A.
- Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19:S227–S237. CrossRef
- Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31:537–547. CrossRef
- Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50:1175–1183. CrossRef
- Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon alpha-2b and ribavirin therapy for chronic hepatitis C. Psychosomatics. 2003;44:104–112. CrossRef
- Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 2005;40:S286–S291. CrossRef
- All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C
Digestive Diseases and Sciences
Volume 59, Issue 4 , pp 872-880
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Hepatitis C
- Liver disease
- Hepatocellular carcinoma
- Antiviral therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Psychiatry (116A), Minneapolis Veterans Affairs Health Care System, One Veterans Drive, Minneapolis, MN, 55417, USA
- 2. Departments of Psychiatry, University of Minnesota-Medical School, Minneapolis, MN, USA
- 3. Departments of Medicine, University of Minnesota-Medical School, Minneapolis, MN, USA
- 4. Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA